Dashboard
CRISPR Therapeutics AG
CRSPNASDAQFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 19Ownership changeSEC
SEC Form 4 insider transaction filing.
- Nov 12Trial initiationClinicalTrials.gov
CRISPR Therapeutics begins recruiting for Phase 1/2 trial of CTX340 in hypertension (NCT07758634).
- Nov 6Ownership changeSEC
SEC Form 4 insider beneficial ownership change report filed.
- Nov 5Trial readoutClinicalTrials.gov
CRISPR Therapeutics completes Phase 1 trial NCT05795595 of CTX131 in relapsed/refractory solid tumors
- Nov 2Financial resultsSEC
CRISPR Therapeutics AG filed 8-K (items 2.02, 9.01) disclosing financial results.
- Oct 28Ownership changeSEC
SEC Form 4 insider transaction filing.
- Oct 28Ownership changeSEC
SEC Form 4 filing reporting change in beneficial ownership by insider at CRISPR Therapeutics.
- Oct 28Ownership changeSEC
Form 4 insider transaction filing.
- Oct 28Ownership changeSEC
SEC Form 4 filing reporting change in insider ownership for CRISPR Therapeutics AG.
- Oct 21Ownership changeSEC
SEC Form 4 filing reporting change in beneficial ownership.
- Oct 20Ownership changeSEC
Form 4 filing reporting change in insider ownership at CRISPR Therapeutics AG.
- Oct 20Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.
- Oct 19LeadershipSEC
8-K reports item 5.02 leadership change (director/officer departure or appointment).
- Oct 16Ownership changeSEC
SEC Form 4 insider transaction filing for CRISPR Therapeutics AG.
- Oct 15Ownership changeSEC
Form 4 insider transaction filing for CRISPR Therapeutics AG.
- Oct 15Ownership changeSEC
SEC Form 4 insider transaction filing by CRISPR Therapeutics AG.
- Oct 8Ownership changeSEC
Form 4 insider trading report filed 2026-10-08.
- Sep 24Ownership changeSEC
Form 4 insider ownership change filing
- Sep 24Trial initiationClinicalTrials.gov
Long-term follow-up study (NCT06208878) of CRISPR CAR T therapies updated to ENROLLING_BY_INVITATION status.
- Sep 22Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease.
Not financial advice — research and opinion only. Disclosures